DK171119B1 - AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin - Google Patents
AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin Download PDFInfo
- Publication number
- DK171119B1 DK171119B1 DK177286A DK177286A DK171119B1 DK 171119 B1 DK171119 B1 DK 171119B1 DK 177286 A DK177286 A DK 177286A DK 177286 A DK177286 A DK 177286A DK 171119 B1 DK171119 B1 DK 171119B1
- Authority
- DK
- Denmark
- Prior art keywords
- aids
- protein
- envelope protein
- expression vector
- env
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 147
- 238000000034 method Methods 0.000 title claims abstract description 55
- 241000725303 Human immunodeficiency virus Species 0.000 title claims abstract description 32
- 239000013604 expression vector Substances 0.000 title claims abstract description 27
- 101710091045 Envelope protein Proteins 0.000 title claims abstract description 19
- 101710188315 Protein X Proteins 0.000 title claims abstract description 19
- 108010003533 Viral Envelope Proteins Proteins 0.000 title claims description 20
- 229960005486 vaccine Drugs 0.000 title claims description 16
- 238000012360 testing method Methods 0.000 title claims description 8
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 4
- 210000004369 blood Anatomy 0.000 claims abstract description 18
- 239000008280 blood Substances 0.000 claims abstract description 18
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 138
- 102000004169 proteins and genes Human genes 0.000 claims description 89
- 239000013612 plasmid Substances 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 43
- 108010078428 env Gene Products Proteins 0.000 claims description 34
- 241000700605 Viruses Species 0.000 claims description 31
- 102100034353 Integrase Human genes 0.000 claims description 30
- 239000002773 nucleotide Substances 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 125000003729 nucleotide group Chemical group 0.000 claims description 23
- 239000000427 antigen Substances 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 19
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 241000588724 Escherichia coli Species 0.000 claims description 16
- 102100034349 Integrase Human genes 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 238000004458 analytical method Methods 0.000 claims description 12
- 230000036039 immunity Effects 0.000 claims description 11
- 238000013519 translation Methods 0.000 claims description 11
- 238000002955 isolation Methods 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 7
- 101710132601 Capsid protein Proteins 0.000 claims description 6
- 101710094648 Coat protein Proteins 0.000 claims description 6
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 claims description 6
- 101710125418 Major capsid protein Proteins 0.000 claims description 6
- 101710141454 Nucleoprotein Proteins 0.000 claims description 6
- 101710083689 Probable capsid protein Proteins 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000005406 washing Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 3
- 210000004962 mammalian cell Anatomy 0.000 claims description 3
- 241001288713 Escherichia coli MC1061 Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 230000002068 genetic effect Effects 0.000 claims description 2
- 238000002649 immunization Methods 0.000 claims description 2
- 230000010076 replication Effects 0.000 claims description 2
- 230000003362 replicative effect Effects 0.000 claims description 2
- 230000001131 transforming effect Effects 0.000 claims description 2
- VBKIFHUVGLOJKT-FKZODXBYSA-N Asn-Thr Chemical compound C[C@@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)N)O VBKIFHUVGLOJKT-FKZODXBYSA-N 0.000 claims 2
- 239000007790 solid phase Substances 0.000 claims 2
- 241000192125 Firmicutes Species 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000001566 pro-viral effect Effects 0.000 abstract description 12
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000010998 test method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 80
- 108020004414 DNA Proteins 0.000 description 50
- 239000012634 fragment Substances 0.000 description 25
- 108090000765 processed proteins & peptides Proteins 0.000 description 25
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 20
- 108091028043 Nucleic acid sequence Proteins 0.000 description 20
- 235000001014 amino acid Nutrition 0.000 description 19
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 229940024606 amino acid Drugs 0.000 description 17
- 239000013598 vector Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 108700004025 env Genes Proteins 0.000 description 14
- 101150030339 env gene Proteins 0.000 description 14
- 230000001580 bacterial effect Effects 0.000 description 13
- 239000013613 expression plasmid Substances 0.000 description 12
- 241001430294 unidentified retrovirus Species 0.000 description 12
- 238000012216 screening Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 210000000170 cell membrane Anatomy 0.000 description 10
- 238000010367 cloning Methods 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 238000012300 Sequence Analysis Methods 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000013599 cloning vector Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 229960000723 ampicillin Drugs 0.000 description 8
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 108091008146 restriction endonucleases Proteins 0.000 description 8
- 102000053602 DNA Human genes 0.000 description 7
- 108020004511 Recombinant DNA Proteins 0.000 description 7
- 230000000890 antigenic effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000003776 cleavage reaction Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 230000007017 scission Effects 0.000 description 7
- 230000002209 hydrophobic effect Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 102000004594 DNA Polymerase I Human genes 0.000 description 5
- 108010017826 DNA Polymerase I Proteins 0.000 description 5
- 206010020460 Human T-cell lymphotropic virus type I infection Diseases 0.000 description 5
- 208000008771 Lymphadenopathy Diseases 0.000 description 5
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 108091081024 Start codon Proteins 0.000 description 5
- 208000000389 T-cell leukemia Diseases 0.000 description 5
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000000120 cytopathologic effect Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 208000018555 lymphatic system disease Diseases 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 241000714195 Aids-associated retrovirus Species 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 102000012410 DNA Ligases Human genes 0.000 description 4
- 108010061982 DNA Ligases Proteins 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 239000004098 Tetracycline Substances 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229960002180 tetracycline Drugs 0.000 description 4
- 229930101283 tetracycline Natural products 0.000 description 4
- 235000019364 tetracycline Nutrition 0.000 description 4
- 150000003522 tetracyclines Chemical class 0.000 description 4
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 description 3
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 101000582398 Staphylococcus aureus Replication initiation protein Proteins 0.000 description 3
- 201000006966 adult T-cell leukemia Diseases 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000010324 immunological assay Methods 0.000 description 3
- 238000013198 immunometric assay Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 150000002972 pentoses Chemical class 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000014621 translational initiation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Chemical group OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000701959 Escherichia virus Lambda Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 108020005038 Terminator Codon Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 101150073130 ampR gene Proteins 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000002144 chemical decomposition reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000000652 homosexual effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 101150061166 tetR gene Proteins 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 108010052418 (N-(2-((4-((2-((4-(9-acridinylamino)phenyl)amino)-2-oxoethyl)amino)-4-oxobutyl)amino)-1-(1H-imidazol-4-ylmethyl)-1-oxoethyl)-6-(((-2-aminoethyl)amino)methyl)-2-pyridinecarboxamidato) iron(1+) Proteins 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010001513 AIDS related complex Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 101100004280 Caenorhabditis elegans best-2 gene Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241000701533 Escherichia virus T4 Species 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000005599 HTLV-I Infections Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- KVSBQLNBMUPADA-AVGNSLFASA-N Leu-Val-Val Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KVSBQLNBMUPADA-AVGNSLFASA-N 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000005384 Pneumocystis Pneumonia Diseases 0.000 description 1
- 206010073755 Pneumocystis jirovecii pneumonia Diseases 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000702208 Shigella phage SfX Species 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 description 1
- 208000037913 T-cell disorder Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011210 chromatographic step Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 108700042226 ras Genes Proteins 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- AIDS & HIV (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US72502185A | 1985-04-19 | 1985-04-19 | |
US72502185 | 1985-04-19 |
Publications (3)
Publication Number | Publication Date |
---|---|
DK177286D0 DK177286D0 (da) | 1986-04-17 |
DK177286A DK177286A (da) | 1986-10-20 |
DK171119B1 true DK171119B1 (da) | 1996-06-17 |
Family
ID=24912812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK177286A DK171119B1 (da) | 1985-04-19 | 1986-04-17 | AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin |
Country Status (12)
Country | Link |
---|---|
US (1) | US6077935A (no) |
EP (1) | EP0199301B2 (no) |
JP (1) | JPS6212799A (no) |
AT (1) | ATE99330T1 (no) |
AU (1) | AU595511B2 (no) |
CA (1) | CA1341410C (no) |
DE (1) | DE3689447T2 (no) |
DK (1) | DK171119B1 (no) |
ES (1) | ES8706209A1 (no) |
FI (1) | FI861626A (no) |
NO (1) | NO861546L (no) |
NZ (1) | NZ215867A (no) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8423659D0 (en) | 1984-09-19 | 1984-10-24 | Pasteur Institut | Cloned dna sequences |
GB8429099D0 (en) | 1984-11-16 | 1984-12-27 | Pasteur Institut | Closed dna sequences |
US7205102B1 (en) | 1983-09-15 | 2007-04-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated virus (LAV) and proteins encoded by said LAV genomic RNA |
US7232654B1 (en) | 1983-09-15 | 2007-06-19 | Institut Pasteur | DNA sequence of the LTR region of human immunodeficiency virus type 1 (HIV-1) |
US7351412B1 (en) | 1983-12-05 | 2008-04-01 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
US7045130B1 (en) | 1984-10-18 | 2006-05-16 | Institut Pasteur | Antibodies against antigens of human immunodeficiency virus (HIV-1) |
US5980900A (en) * | 1984-10-18 | 1999-11-09 | Institut Pasteur And Centre National De La Recherche Scientifique | Amino acid DNA sequences related to genomic RNA of human immunodeficiency virus (HIV-1) |
US5705612A (en) | 1984-10-18 | 1998-01-06 | Institut Pasteur And Centre National De La Recherche Scientifique | NEF peptide encoded by human immunodefiency virus type 1 (HIV-1) |
US6894152B1 (en) | 1984-11-16 | 2005-05-17 | Institut Pasteur | Cloned DNA sequences related to the genomic RNA of lymphadenopathy-associated-virus (LAV) and proteins encoded by said LAV genomic RNA |
JPS62501263A (ja) * | 1984-11-29 | 1987-05-21 | スクリツプス クリニツク アンド リサ−チ フアウンデ−シヨン | 脱グリコシル化ウイルス糖タンパク質に関連するポリペプチド類および抗体 |
IE64785B1 (en) * | 1985-04-08 | 1995-09-06 | Genetic Systems Corp | Expression of immunologically reactive viral proteins |
FR2593519B1 (fr) * | 1985-09-25 | 1994-01-07 | Oncogen | Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin |
GR862412B (en) * | 1985-09-25 | 1987-01-23 | Oncogen | Vaccines and immuinoassays for acquired immune deficiency syndrome |
US4734362A (en) * | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4925784A (en) * | 1986-04-04 | 1990-05-15 | Hoffmann-La Roche Inc. | Expression and purification of an HTLV-III gag/env gene protein |
US5017688A (en) * | 1986-06-12 | 1991-05-21 | Biogen, Inc. | Peptides involved in the pathogenesis of HIV infection |
US4943627A (en) * | 1986-06-12 | 1990-07-24 | Biogen, Inc. | Peptides involved in the pathogenesis of HIV infection |
US5087557A (en) * | 1986-06-23 | 1992-02-11 | Genetic Systems Corporation | Human monoclonal antibody to lymphadenopathy-associated virus |
EP0525828A3 (en) * | 1986-08-01 | 1993-02-24 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
NZ221440A (en) * | 1986-08-20 | 1991-11-26 | Genetic Systems Corp | Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections |
US5166050A (en) * | 1986-08-20 | 1992-11-24 | Bristol-Myers Squibb Company | Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections |
ATE154808T1 (de) * | 1987-01-16 | 1997-07-15 | Pasteur Institut | Peptide mit den immunologischen eigenschaften von hiv-2 |
FR2610632B1 (fr) * | 1987-02-11 | 1990-12-21 | Pasteur Institut | Peptides caracteristiques des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida |
US4861707A (en) * | 1987-02-02 | 1989-08-29 | E. I. Du Pont De Nemours And Company | Human immunodeficiency virus antigen |
CA1341277C (en) * | 1987-03-16 | 2001-07-31 | Roland Keith Mcgready | Anti-paratopic antibody and a method of its manufacture |
US4921787A (en) * | 1987-05-01 | 1990-05-01 | Cambridge Bioscience Corporation | Detection of antibodies to human immunodeficiency virus by agglutination of antigen coated latex |
FR2615623B1 (fr) * | 1987-05-22 | 1992-06-19 | Transgene Sa | Test de diagnostic du sida base sur la mise en evidence d'une diversite de la reponse isotypique, vaccins et serotherapies |
US5981278A (en) * | 1987-05-29 | 1999-11-09 | Tanox, Inc. | Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS |
US6657050B1 (en) | 1987-05-29 | 2003-12-02 | Tanox, Inc. | Chimeric viral-neutralizing immunoglobulins |
US5834599A (en) * | 1987-05-29 | 1998-11-10 | Tanox Biosystems, Inc. | Immunoconjugates which neutralize HIV-1 infection |
DE3854857T2 (de) * | 1987-06-10 | 1996-08-22 | Immune Response Corp Inc | Verhütung und behandlung einer retrovirenkrankheit |
US5256767A (en) * | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
NO881501L (no) * | 1987-10-09 | 1989-04-10 | Repligen Corp | Rekombinante htlv-111-proteiner og anvendelser av disse. |
EP0311228A3 (en) * | 1987-10-09 | 1990-05-02 | Repligen Corporation | Recombinant polypeptides and their uses, including assay for aids virus |
US5254458A (en) * | 1987-10-30 | 1993-10-19 | Abbott Laboratories | Immunoassays using antigens produced in heterologous organisms |
US5763160A (en) * | 1988-02-12 | 1998-06-09 | United Biomedical, Inc. | Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines |
EP0330359A3 (en) * | 1988-02-25 | 1991-06-05 | Bio-Rad Laboratories, Inc. | Composition useful in the diagnosis and treating of hiv-1 infection |
FR2635532B1 (fr) * | 1988-07-29 | 1992-05-22 | Pasteur Institut | Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant |
CA2003383A1 (en) * | 1988-11-23 | 1990-05-23 | Sushil G. Devare | Synthetic dna derived recombinant hiv antigens |
FR2640877A1 (no) * | 1988-12-06 | 1990-06-29 | Centre Nat Rech Scient | |
DE4405810A1 (de) | 1994-02-23 | 1995-08-24 | Behringwerke Ag | Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung |
US7935805B1 (en) | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
WO2000039304A2 (en) | 1998-12-31 | 2000-07-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
AU2596600A (en) | 1998-12-31 | 2000-07-31 | Chiron Corporation | Modified hiv env polypeptides |
US6602705B1 (en) | 1998-12-31 | 2003-08-05 | Chiron Corporation | Expression of HIV polypeptides and production of virus-like particles |
US7211659B2 (en) | 2001-07-05 | 2007-05-01 | Chiron Corporation | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof |
US20030170614A1 (en) | 2001-08-31 | 2003-09-11 | Megede Jan Zur | Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
AU2002316578A1 (en) | 2001-08-31 | 2003-03-18 | Chiron Corporation | Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4237224A (en) * | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
DE2814039C3 (de) * | 1978-03-31 | 1981-02-19 | Gesellschaft Fuer Biotechnologische Forschung Mbh (Gbf), 3300 Braunschweig | Verfahren zur Herstellung von Hybrid-Bakterien |
EP0151579B1 (en) * | 1983-04-27 | 1995-09-06 | The President And Fellows Of Harvard College | Method and products for detection of human t cell leukemia virus |
US4743678A (en) * | 1983-04-27 | 1988-05-10 | President And Fellows Of Harvard College | Method and products for detection of human T cell leukemia virus |
EP0152030A3 (en) * | 1984-02-03 | 1986-08-13 | Juridical Foundation Japanese Foundation for Cancer Research | Adult t cell leukemia virus antigen polypeptide |
US4520113A (en) * | 1984-04-23 | 1985-05-28 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Serological detection of antibodies to HTLV-III in sera of patients with AIDS and pre-AIDS conditions |
IL76082A (en) * | 1984-08-22 | 1991-07-18 | Us Health | Molecular clones of the genome of htlv-iii and a process for the preparation thereof |
IE64006B1 (en) * | 1984-10-18 | 1995-06-28 | Pasteur Institut | Antigens particulary envelope antigens of the virus of lymphadenopathies and of the acquired immune-deficiency syndrome and virus process for producing virus envelope antigens use of said antigens in the preparation of immunogenic compositions or for the diagnosis of the presence of antibodies against this virus |
CA1341423C (en) * | 1984-10-31 | 2003-03-04 | Paul A. Luciw | Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome |
US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
EP0187041B1 (en) * | 1984-12-24 | 1996-05-15 | Genentech, Inc. | Fusions of AIDS-related polypeptides |
IE64785B1 (en) * | 1985-04-08 | 1995-09-06 | Genetic Systems Corp | Expression of immunologically reactive viral proteins |
US4629783A (en) * | 1985-04-29 | 1986-12-16 | Genetic Systems Corporation | Synthetic antigen for the detection of AIDS-related disease |
-
1986
- 1986-04-17 FI FI861626A patent/FI861626A/fi not_active Application Discontinuation
- 1986-04-17 NZ NZ215867A patent/NZ215867A/xx unknown
- 1986-04-17 DK DK177286A patent/DK171119B1/da not_active IP Right Cessation
- 1986-04-18 NO NO861546A patent/NO861546L/no unknown
- 1986-04-18 DE DE86105371T patent/DE3689447T2/de not_active Expired - Lifetime
- 1986-04-18 JP JP61089830A patent/JPS6212799A/ja active Pending
- 1986-04-18 AT AT86105371T patent/ATE99330T1/de not_active IP Right Cessation
- 1986-04-18 ES ES554155A patent/ES8706209A1/es not_active Expired
- 1986-04-18 CA CA000507045A patent/CA1341410C/en not_active Expired - Lifetime
- 1986-04-18 AU AU56363/86A patent/AU595511B2/en not_active Expired
- 1986-04-18 EP EP86105371A patent/EP0199301B2/en not_active Expired - Lifetime
-
1991
- 1991-12-20 US US07/811,896 patent/US6077935A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DK177286D0 (da) | 1986-04-17 |
EP0199301A1 (en) | 1986-10-29 |
FI861626A (fi) | 1986-10-20 |
AU595511B2 (en) | 1990-04-05 |
NO861546L (no) | 1986-10-20 |
CA1341410C (en) | 2002-12-17 |
JPS6212799A (ja) | 1987-01-21 |
ES8706209A1 (es) | 1987-06-01 |
FI861626A0 (fi) | 1986-04-17 |
AU5636386A (en) | 1986-10-23 |
DK177286A (da) | 1986-10-20 |
ES554155A0 (es) | 1987-06-01 |
EP0199301B1 (en) | 1993-12-29 |
US6077935A (en) | 2000-06-20 |
EP0199301B2 (en) | 1997-07-09 |
DE3689447D1 (de) | 1994-02-10 |
NZ215867A (en) | 1989-10-27 |
DE3689447T2 (de) | 1994-04-28 |
ATE99330T1 (de) | 1994-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK171119B1 (da) | AIDS-viruskappeprotein, ekspressionsvektor bærende viruskappeproteinet, transformanter transformeret med ekspressionsvektoren, fremgangsmåde til fremstilling af viruskappeproteinet, fremgangsmåde til detektion af AIDS-antistoffer, fremgangsmåde til bestemmelse af AIDS-virus, vaccine mod AIDS, antistoffer mod viruskappeproteinet samt anvendelse af dette til fremstilling af en vaccine og til testnin | |
DK172274B1 (da) | HTLV-III-virusprotein, DNA-sekvens, der koder herfor, fremgangsmåde til fremstilling heraf, fremgangsmåde til detektion af AIDS-virus samt antistoffer mod AIDS-virus | |
Aldovini et al. | Synthesis of the complete trans-activation gene product of human T-lymphotropic virus type III in Escherichia coli: demonstration of immunogenicity in vivo and expression in vitro. | |
EP0230222A1 (en) | Expression of HTLV-III gag-Gene | |
JP2752329B2 (ja) | リンパ節症及び後天性免疫不全症候群のウイルスのエンベロープ抗原の製造方法 | |
US5221610A (en) | Diagnostic method and composition for early detection of HIV infection | |
Steimer et al. | Recombinant polypeptide from the endonuclease region of the acquired immune deficiency syndrome retrovirus polymerase (pol) gene detects serum antibodies in most infected individuals | |
JPS61173782A (ja) | リンパ節疾患症候群および/または後天性免疫不全症候群に関連する組換えウイルスタンパク質 | |
EP0436634A1 (en) | Hiv proteins and peptides useful in the diagnosis, prophylaxis or therapy of aids | |
NO812341L (no) | Syntetisk peptid-, spesifikk antigenisk determinant og fremgangsmaate til fremstilling av antigeniske materialer derfra | |
WO1987007906A1 (en) | Variants of lav viruses, their dna- and protein-components and their uses, particularly for diagnostic purposes and for the preparartion of immunogenic compositions | |
US6296807B1 (en) | Kits for the detection of human immunodeficiency virus type 2 (HIV-2) antigens | |
DK167158B1 (da) | Dna-sekvens, der koder for et protein, der er immunologisk reaktivt mod antistoffer for lav, et rekombinantplasmid indeholdende dna-sekvensen, bakteriecelle med rekombinantplasmidet, fremgangsmaade til fremstilling af proteiner som er immunologisk reaktive med antistoffer for lav, samt proteinet og anvendelser af proteinet | |
Franchini et al. | Spectrum of natural antibodies against five HTLV-III antigens in infected individuals: correlation of antibody prevalence with clinical status | |
Tencza et al. | Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein | |
Le Grice et al. | A single 66-kilodalton polypeptide processed from the human immunodeficiency virus type 2 pol polyprotein in Escherichia coli displays reverse transcriptase activity | |
US5780038A (en) | HIV-2 envelope polypeptides | |
EP0306219A2 (en) | Novel HIV proteins and peptides useful in the diagnosis, prophylaxis or therapy of AIDS | |
US5874533A (en) | HIV-2 envelope polypeptides | |
KR960005181B1 (ko) | 재조합 htlv-ⅲ 단백질 및 이의 용도 | |
WO1987002989A1 (en) | Aids virus gene expression | |
JP3439208B2 (ja) | Htlv−▲i▼及びhtlv−▲ii▼ペプチド抗原及び方法 | |
Samuel et al. | Bacterial expression and characterization of nine polypeptides encoded by segments of the envelope gene of human immunodeficiency virus | |
US5773210A (en) | Acquired immune deficiency syndrome (AIDS) viral envelope protein and method of testing for AIDS | |
JPH01193299A (ja) | 組替htlv−3蛋白質及びその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B1 | Patent granted (law 1993) | ||
PUP | Patent expired |